* severe co-morbidity with life expectancy \<3 months according to investigators assessment * asat/alat \> 5 times the upper limit of normal * acute co-morbidity within 7 days before inclusion such as myocardial infarction or unstable angina pectoris (not including troponin elevation due to infection) * pregnancy or breast feeding * any reason why, in the opinion of the investigators, the patient should not participate * subject participates in a potentially confounding drug or device trial during the course of the study * already receiving the study drug * renal failure (egrf \< 30 ml/min) or dialysis/continuous veno-venous hemofiltration

* severe co-morbidity with life expectancy \<3 months according to investigators assessment * asat/alat \> 5 times the upper limit of normal * acute co-morbidity within 7 days before inclusion such as myocardial infarction or unstable angina pectoris (not including troponin elevation due to infection) * pregnancy or breast feeding * any reason why, in the opinion of the investigators, the patient should not participate * subject participates in a potentially confounding drug or device trial during the course of the study * already receiving the study drug * renal failure (egrf \< 30 ml/min) or dialysis/continuous veno-venous hemofiltration

- severe co-morbidity with life expectancy <3 months according to investigators assessment - asat/alat > 5 times the upper limit of normal - acute co-morbidity within 7 days before inclusion such as myocardial infarction or unstable angina pectoris (not including troponin elevation due to infection) - pregnancy or breast feeding - any reason why, in the opinion of the investigators, the patient should not participate - subject participates in a potentially confounding drug or device trial during the course of the study - already receiving the study drug - renal failure (egrf < 30 ml/min) or dialysis/continuous veno-venous hemofiltration

- severe co-morbidity with life expectancy <3 months according to investigators assessment - asat/alat > 5 times the upper limit of normal - acute co-morbidity within 7 days before inclusion such as myocardial infarction or unstable angina pectoris (not including troponin elevation due to infection) - pregnancy or breast feeding - any reason why, in the opinion of the investigators, the patient should not participate - subject participates in a potentially confounding drug or device trial during the course of the study - already receiving the study drug - renal failure (egrf < 30 ml/min) or dialysis/continuous veno-venous hemofiltration